ABSTRACT
OBJECTIVE: Our study focuses on the determination and evaluation of TGF-ß1 levels of patients receiving hemodialysis treatment because of chronic renal failure. BACKGROUND: Chronic renal failure, characterized by irreversible loss of renal function, is a major public health problem in the world. Transforming growth factor-beta is a multifunctional cytokine involved in the cellular growth, differentiation, migration, apoptosis and immune regulation. Among the three TGF-ß isoforms, TGF-ß1 plays a key role in the pathogenesis of renal diseases. METHODS: We studied 24 patients who were on regular hemodialysis, with non-diabetic nephropathy. 20 healthy people who proved to be in a good state of health and free from any signs of chronic diseases or disorders were enrolled as a control group. Serum samples were collected both before and after hemodialysis treatment from each patient. TGF-ß1 levels were determined by Enzyme Immunoassay method. RESULTS: TGF-ß1 levels were found significantly higher in the hemodialysis patients than those of the control groups. Also, the TGF-ß1 was significantly reduced after hemodialysis treatment but it was still higher than in control groups. CONCLUSION: This result indicates that hemodialysis is an effective treatment method to decrease the serum TGF-B1 levels. Nevertheless, this decrease is not enough to reduce existing risks (Tab. 1, Fig. 2, Ref. 28).
